Summary of Alumis Conference Call Company Overview - Company: Alumis - Lead Asset: Envutuzitinib, a TYK2 inhibitor - Age: Approximately 4.5 years old, approaching 5 years Key Points and Arguments Product Development and Pipeline - Envutuzitinib is the lead molecule targeting autoimmune diseases, particularly psoriasis and lupus [2][3] - The company has three clinical assets, all beyond phase one, with the lead indication being psoriasis [3] - Psoriasis Program: Expected data readout in early Q1 next year, with confidence in competitive positioning based on preclinical and phase two data [3][4] - Lupus Program: Phase 2b trial designed as a pivotal trial, with data expected in Q3 next year [4] Competitive Landscape - Anticipation of multiple readouts in the TYK2 space from competitors next year [6] - The company plans to partner Envutuzitinib, which could influence overall business strategy [6] Clinical Trial Insights - Phase Two Data: Envutuzitinib showed a clear dose response, with the ability to dose-increase without reduction, distinguishing it from competitors [9][10] - Enrollment Success: Rapid enrollment attributed to the simplicity and safety of the drug, leading to over-enrollment in trials [12][13] - Demographics: Phase two primarily involved U.S. and Canadian patients, with expectations for more diverse demographics in phase three [15][16] Market Expectations - Aiming for PASI 90 response rates between 60-70% in phase three, which would position the product competitively [23][24] - Potential NDA filing could occur next year, pending data collection on durability and maintenance [25] Lupus Opportunity - The LUMA study involves over 400 patients, with data expected in Q3 next year [29] - The primary endpoint is BICLA, with secondary endpoints including SRI-4 [31] Future Indications - If lupus trial is successful, it may open opportunities in other interferon-driven diseases [35] - Interest in exploring indications for inflammatory bowel disease (IBD) based on competitor trials [35] Other Assets - A-005: A brain-penetrant molecule, with phase one completed and plans to start phase two in MS in the first half of next year [36][37] - Lonigutamab: Under evaluation for potential development, with ongoing assessments of competitive landscape [40] Financial Health - The company reported a strong balance sheet with over $480 million at the end of Q2, providing a cash runway into 2027 [41]
Alumis (NasdaqGS:ALMS) FY Conference Transcript